Cost gatekeepers give final ‘no’ to Pfizer’s targeted cancer drug Xalkori

Clinically effective but not cost-effective. That's what U.K. watchdogs have determined about Pfizer's targeted lung cancer drug, Xalkori. Despite a discount offer from Pfizer, the National Institute…
Read the full story: FiercePharma News